Validated Clinical Performance

HEALTHCARE &
BREATH
ANALYSIS

The same AACTS® active sampling and IMS physics that secures defense installations now delivers non-invasive, point-of-care disease diagnostics. No reagents. No laboratory. Results in 20 seconds. Validated for tuberculosis screening with 95.7% sensitivity.

Request Clinical Partnership View System Specifications

95.7%

Clinical Sensitivity

Tuberculosis detection — validated use case

91.3%

Clinical Specificity

Validated TB screening performance

0.935

ROC AUC

Strong discriminative performance

<20s

Result Time

From breath sample to identification

Clinical Mechanism

VOC Biomarker Detection

Human breath contains hundreds of volatile organic compounds (VOCs) — many of which are specific biomarkers produced by pathogen metabolism or host biochemical responses to disease. AACTS® captures and identifies these biomarker signatures using the same TRU-RAD IMS engine deployed in defense applications.

The breath sampling adapter integrates directly with the AACTS-3000 analyzer. 7–10 forced expirations are directed onto a standard filter card. Thermal desorption releases captured VOCs into the IMS drift tube. The DDMS engine, configured for VOC biomarker mode, identifies compound signatures against the clinical biomarker library.

Non-Invasive Clinical Advantage

Unlike sputum culture (days), GeneXpert (hours), or IGRA blood tests, AACTS® breath analysis requires no patient preparation, no biological sample handling, no reagents, and delivers results in under 20 seconds — making mass screening at the point-of-care operationally practical for the first time.

Clinical Workflow — TB Screening

Patient Breath Collection

7–10 forced expirations directed onto filter card via breath sampling adapter. Non-invasive. No patient preparation required.

Filter Card Processing

Filter card inserted into AACTS-3000 analyzer. Thermal desorption cycle releases captured VOC biomarkers into the IMS drift tube.

IMS Analysis

TRU-RAD X-AIMS separates VOC compounds by drift time. DDMS engine compares spectral signature against validated biomarker library.

Result — Under 20 Seconds

Positive or negative identification displayed. No reagents consumed. Filter card regenerated for next patient.

Clinical Performance Data — TB Use Case

Validated Diagnostic Performance

Clinical validation of the AACTS® breath analyzer for tuberculosis screening demonstrates strong discriminative performance across sensitivity, specificity, and overall diagnostic accuracy metrics.

95.7%

Sensitivity

TB detection rate

91.3%

Specificity

True negative rate

0.935

ROC AUC

Discriminative accuracy

Zero

Reagents

No consumables

Clinical Data Note

Performance data presented reflects validated clinical studies for the tuberculosis use case. Additional disease applications (respiratory diseases, metabolic disorders, infectious disease detection) are under active research and development. Contact our clinical partnerships team for detailed study data and research collaboration opportunities.

Application Scenarios

Healthcare Deployment Scenarios

TB Mass Screening

High-throughput community screening programs in high-burden TB settings. No laboratory infrastructure required. Results per patient in under 20 seconds. Suitable for mobile screening units.

Low-Resource Settings

Point-of-care deployment in areas without laboratory access. No electricity required for breath sample collection. Battery-powered analyzer option. No cold chain for reagents.

Military Health Screening

Force health protection screening for TB and respiratory infections in military personnel. Same AACTS-3000 hardware as deployed for security applications — dual-use capability.

Border & Port of Entry

Infectious disease screening at immigration checkpoints and ports of entry. Non-invasive. High-throughput. Supports pandemic preparedness and public health border control operations.

Research & Surveillance

VOC biomarker research for new disease applications. Epidemiological surveillance programs. Academic collaboration for expanding the clinical biomarker library.

Pandemic Preparedness

Rapid deployment capability for emerging infectious disease outbreaks. Expandable biomarker library allows new pathogen signatures to be added via software update to deployed systems.

ICMR · WHO · National TB Programs · Public Health Authorities

Partner on Clinical Innovation

We work with national TB programs, public health authorities, academic research institutions, and international health organizations on clinical validation and deployment programs.